US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Enzymatica: ColdZyme® Mouth Spray – for treating the common cold – to be introduced by the Swedish Apotek Hjärtat pharmacy chain

Enzymatica has concluded an agreement with Apotek Hjärtat, Sweden’s second largest pharmacy chain. During February 2013, Enzymatica’s medical device product, ColdZyme® Mouth Spray, will be introduced as part of the product range at Apotek Hjärtat.“The agreement signed with the Apotek Hjärtat pharmacy chain serves as further confirmation of the interest in our products. The Apotek Hjärtat pharmacy chain is Sweden’s second largest pharmacy group, with some 270 pharmacies nationwide,” notes Michael Edelborg Christensen, CEO at Enzymatica. Enzymatica’s registered product, ColdZyme® Mouth

Enzymatica published in the international journal Infectious Diseases & Therapy – promising method for the prevention of colds using ColdZyme Mouth Spray

A recently published systematic review article in Infectious Diseases & Therapy, authored by Enzymatica’s researchers, elucidates the potential of cold-adapted proteases for the treatment of various illnesses. ColdZyme Mouth Spray may offer promising potential as a medical device treatment in reducing the risk of contracting the common cold. Proteases or proteolytic enzymes have been used therapeutically over a protracted period and have displayed major potential in the treatment of a number of illnesses. Cold-adapted proteases offer greater flexibility and catalytic effectiveness than

Enzymatica signs agreement with the Kronans Droghandel pharmacy chain

Enzymatica has concluded its first commercial agreement. This entails that Enzymatica’s medical device product, ColdZyme® Mouth Spray used against the common cold, will be on sale at the Kronans Droghandel pharmacies in early 2013. “The agreement is, of course, commercially important for us, since the pharmacy chains represent a significant factor in our launch strategy. It has been consistently our goal to launch among the pharmacy chains at the beginning of 2013 and thus it is extra gratifying to be able to deliveron schedule,” says Michael Edelborg Christensen, CEO at Enzymatica.

Enzymatica’s ColdZyme® Mouth Spray against common cold is registered with the Swedish Medical Product Agency

Enzymatica AB (publ) has registered ColdZyme ® Mouth Spray with the Swedish Medical Product Agency as a medical device, Class I. The product is intended for the prevention and treatment of common cold, it may also reduce the duration, if used in the early stages of common cold. The ColdZyme® Mouth Spray is based on an enzyme derived from the deep-sea cod that has been shown to have very good therapeutic characteristics. Negotiations are ongoing with the major pharmacy chains and wholesalers in Sweden for the upcoming large-scale launches in Sweden and the other Nordic countries. · The

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe